Lancet
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
Randomised trial in 302 peopleInterventions
Double-blind, placebo-controlled, multicentre, registered NCT01524783
The paper
The University of Texas MD Anderson Cancer Center; Charité - Universitätsmedizin Berlin
Lancet, 17 Dec 2015
